|
Synonyms: HuMab 002 [2] | LC1004-002 | RO-4905417 | RO4905417
Compound class:
Antibody
Comment: Inclacumab (formerly RO4905417) is an IgG4κ monoclonal antobody that targets selectin P (CD62; SELP) [2] that was initially designed for potential to promote anti-inflammatory and antithrombotic effects as a mechanism to reduce atherosclerosis. It blocks the interaction between selectin P and its primary ligand, P-selectin glycoprotein ligand-1 (PSGL-1). Inclacumab was later repositioned to reduce vaso-occlusive crises in patients with sickle cell disease.
|
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 9512 | inclacumab |
| Synonyms |
|
| HuMab 002 [2] | LC1004-002 | RO-4905417 | RO4905417 | |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 402 |
| Other databases | |
| GtoPdb PubChem SID | 479821103 |
| Search PubMed clinical trials | inclacumab |
| Search PubMed titles | inclacumab |
| Search PubMed titles/abstracts | inclacumab |
